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We investigated the relationship between sleep-disordered breathing (SDB) and Cheyne-Stokes respiration (CSR) while awake
as well as mortality. Eighty-nine consecutive outpatients (29 females) with congestive heart failure (CHF; left ventricular ejection
fraction, LVEF <45%) were prospectively evaluated. The presence of SDB and of CSR while awake before sleep onset was
investigated by polysomnography. SDB prevalence was 81 and 56%, using apnea-hypopnea index cutoffs >5 and >15,
respectively. CHF etiologies were similar according to the prevalence of SDB and sleep pattern. Males and females were similar
in age, body mass index, and LVEF. Males presented more SDB (P = 0.01), higher apnea-hypopnea index (P = 0.04), more light
sleep (stages 1 and 2; P < 0.05), and less deep sleep (P < 0.001) than females. During follow-up (25 ± 10 months), 27% of the
population died. Non-survivors had lower LVEF (P = 0.01), worse New York Heart Association (NYHA) functional classification
(P = 0.03), and higher CSR while awake (P < 0.001) than survivors. As determined by Cox proportional model, NYHA class IV
(RR = 3.95, 95%CI = 1.37–11.38, P = 0.011) and CSR while  awake with a marginal significance (RR = 2.96, 95%CI = 0.94–9.33,
P = 0.064) were associated with mortality. In conclusion, the prevalence of SDB and sleep pattern of patients with Chagas’
disease were similar to that of patients with CHF due to other etiologies. Males presented more frequent and more severe SDB
and worse sleep quality than females. The presence of CSR while awake, but not during sleep, may be associated with a poor
prognosis in patients with CHF.
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Introduction
Congestive heart failure (CHF) is a highly prevalent
disorder with considerable morbidity and mortality rates
despite advancements in the diagnosis and management
of patients (1). Although the lifetime risk for developing
CHF, regardless of etiology, is 1 in 5 among both men and
women (2), little is known about risk factors for the devel-
opment of CHF in women, perhaps because of the under-
representation of women in cardiovascular clinical trials
(3). Sleep-disordered breathing (SDB) is common in males
with CHF and may be associated with a poor prognosis (4–
7). However, most studies have focused on males and
there are fewer data about the characteristics of sleep in
women with CHF (8,9). In addition, there is no information
about sleep in patients with CHF due to Chagas’ disease,
a neglected disease with profound cardiac consequences
which affects approximately 18 million people worldwide
(10).
SDB in patients with CHF manifests mainly as Cheyne-
Stokes respiration (CSR) and also as obstructive sleep
apnea (OSA) (8,9). CSR is characterized by recurrent
episodes of central apnea, alternating with hyperpnea,
during which there is an crescendo-decrescendo pattern
of tidal volume (11). CSR pattern is not restricted to sleep
but may occur during wakefulness (12,13) as well as
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during exercise (14–16). SDB is associated with recurrent
hypoxia and arousals from sleep, which may contribute to
increased mortality (17). However, studies of the role of
SDB in the prognosis of patients with CHF have provided
conflicting results (4–9,11–19). Several studies did not moni-
tor sleep and relied on limited unattended overnight car-
diorespiratory polygraphy, making it impossible to deter-
mine the contribution of awake CSR to their results (5,9,16).
In contrast to sleep, the CSR pattern during wakefulness
and exercise has been more consistently associated with
a poor prognosis (14–16).
The purpose of the present study was to extend our
knowledge by evaluating consecutive CHF patients from a
single clinic by full polysomnography (PSG) in order to
describe: 1) the presence of SDB and characteristics of
sleep according to etiology, including patients with Chagas’
disease, 2) the presence of SDB and the characteristics of
sleep in men and women, and 3) the relationship between
patterns of SDB and CSR while awake with mortality.
Patients and Methods
Patient selection
Consecutive patients with CHF were recruited from the
outpatient Heart Failure Unit of the Heart Institute (Instituto
do Coração, Hospital das Clínicas, Faculdade de Medi-
cina, Universidade de São Paulo). Patients were eligible if
they had 1) resting left ventricular ejection fraction (LVEF)
of less than 45% as determined by echocardiography, 2)
stable clinical condition as defined by no changes in drug
therapy for at least 1 month before evaluation, and 3) age
between 18 and 75 years. Patients with the following
conditions were excluded: neurological, pulmonary, renal,
and musculoskeletal disease, unstable angina, primary
valvular heart disease, or a previous diagnosis of SDB.
The protocol was approved by the Ethics Committee of our
institution and written informed consent was obtained from
each patient.
Sleep study
Overnight PSG was performed using an EMBLA digital
system (17 channels, EMBLA Medicare, USA). The follow-
ing variables were monitored: electroencephalogram (four
channels: C3–A2, C4–A1, O1–A2, O2–A1), electrooculogram
(two channels: LOC–A2, ROC–A1), electromyogram (two
channels: submental and anterior tibialis muscles) using
surface electrodes, and electrocardiogram (one channel).
Snoring and body position were detected with EMBLA sen-
sors. Airflow was detected with a thermocouple and a pres-
sure flow transducer. Chest and abdominal piezo sensors
monitored respiratory effort. Arterial oxygen saturation (SaO2)
and pulse were recorded with a pulse oximeter.
All PSGs were performed and scored on the basis of
guidelines for sleep studies (20). Arousals were defined
according to the report of the Sleep Disorders Atlas Task
Force of the American Sleep Disorders Association (21).
Apneas, hypopneas, and CSR were defined according to
the report of the American Academy of Sleep Medicine
Task Force (22). Apnea was defined as cessation (>90%
in amplitude) of airflow for at least 10 s. Obstructive apnea
was defined as the absence of airflow in the presence of
respiratory effort. Central apnea was defined as the ab-
sence of airflow with absence of respiratory effort. Hypopnea
was defined as a clear reduction (>50% in amplitude) of
airflow lasting 10 s or more and associated with a drop in
arterial oxyhemoglobin saturation and/or arousal of at
least 3%. CSR was defined by the presence of at least
three consecutive central apneas or hypopneas interposed
by a crescendo-decrescendo pattern of tidal volume. The
apnea-hypopnea index (AHI) was defined by the number
of apneas and hypopneas per hour of sleep (22). We
defined presence of SDB when the AHI was above 15
events/h according to several published reports (23,24).
CSR was established when at least 80% of the respiratory
events were central in nature, interposed by a crescendo-
decrescendo pattern of tidal volume, on the basis of AHI
>15/h.
Awake measurements
Arterial blood gases. Arterial blood samples were drawn
30 min to 1 h before the onset of sleep recording, while
patients were sitting and awake, after at least 10 min of
undisturbed rest, on room air.
Daytime sleepiness. Daytime sleepiness was assessed
by a subjective rating (Epworth Sleepiness Scale, 25) in
each patient before the overnight sleep study.
Respiratory pattern. The respiratory pattern was re-
corded for 10 min while awake in supine position immedi-
ately before the lights were turned off during PSG. CSR
while awake was defined using the same criteria used
during sleep (22).
Follow-up
All patients were followed regularly at the outpatient
clinic. The last follow-up information was obtained by means
of a telephone interview with the patient or with his/her
family. In the case of a deceased patient, mortality informa-
tion, including the date of death, was obtained from the
next of kin.
Statistical analysis
All descriptive data are reported as means ± SD. Differ-
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ences between groups according to respiratory pattern
(CSR, OSA, and no SDB) were analyzed by one-way
ANOVA. Proportions were compared by the Z test. Gender
characteristics were compared by the Student unpaired t-
test or Z test when appropriate. Survival was estimated by
the Kaplan-Meier test and differences between survival
curves were determined by the log-rank test. A Cox propor-
tional model, including all variables with a significant level
<20%, was applied. A P value <0.05 was considered
significant.
Results
A total of 89 patients (60 men) were
enrolled in the study. Eighty-one percent
of the patients were on diuretics, 75% on
digitalis, 90% on vasodilators, and 19%
on ß-blockers. According to the New York
Heart Association (NYHA) functional clas-
sification, 60% of the patients were class
II, 29% were class III, and 11% were class
IV. The etiology of CHF was as follows:
idiopathic (54 patients), ischemic (11 pa-
tients), and Chagas’ disease (24 patients).
The overall prevalence of SDB in the en-
tire group evaluated was 81%, using an
AHI >5 cutoff, and 56%, using an AHI >15
cutoff. Using an AHI >15 cutoff, CSR and
OSA were present in 42 and 11% of pa-
tients with idiopathic etiology, 73 and 0%
of those with ischemic etiology, and 44
and 12% of those with Chagas’ disease
etiology, respectively. The demographic,
clinical and laboratory characteristics of
the whole group are divided according to
Chagas’ disease and remaining etiologies
(non-Chagas’ disease) are summarized
in Table 1. There were no significant dif-
ferences in any of the characteristics ana-
lyzed. The PSG characteristics were simi-
lar between patients with Chagas’ dis-
ease and non-Chagas’ disease (Table 2).
Moreover, we did not find differences in
the presence of SDB among CHF etiolo-
gies (P = 0.4).
Males and females were similar with
respect to age, body mass index, LVEF,
as well as arterial blood gases (Table 3).
The PSG characteristics according to gen-
der are summarized in Table 4. Females
had a better sleep pattern, with signifi-
cantly higher total sleep time (P = 0.03), increased sleep
efficiency (P = 0.03), less light sleep (stage 1 (P = 0.01) and
stage 2 (P = 0.02)), and increased deep sleep (stages 3 +
4 (P < 0.001)). In addition, the prevalence of SDB (P = 0.01)
and AHI (P = 0.03) was significantly lower in females than
in males. Males had higher daytime sleepiness than fe-
males (P = 0.04).
Respiratory pattern while awake was determined in 75
patients (84%). The remaining 14 patients had less than 10
min of respiratory recordings while awake due to either
micro-sleep or movement artifacts. CSR while awake was
Table 1. Demographic, clinical, and laboratory data of patients with congestive
heart failure according to etiology due to Chagas’ and non-Chagas’ disease.
Total Chagas’ disease Non-Chagas’ disease
N = 89 (100%) N = 24 (27%) N = 65 (73%)
Age (years) 58 ± 12 58 ± 9 58 ± 12
BMI (kg/m2) 26 ± 6 25 ± 5 26 ± 5
SBP (mmHg) 121 ± 26 115 ± 32 123 ± 23
DBP (mmHg) 78 ± 13 78 ± 12 78 ± 13
LVEF (%) 35 ± 6 38 ± 5 35 ± 6
Awake arterial blood gases
Arterial pH 7.37 ± 0.3 7.42 ± 0.03 7.37 ± 0.4
PaCO2 (mmHg) 37 ± 5 37 ± 5 37 ± 5
PaO2 (mmHg) 80 ± 9 79 ± 8 80 ± 10
Data are reported as mean ± SD. BMI = body mass index; SBP = systolic blood
pressure; DBP = diastolic blood pressure; LVEF = left ventricular ejection fraction;
PaCO2 = arterial carbon dioxide tension; PaO2 = arterial oxygen tension. There
were no significant differences between groups (Student unpaired t-test).
Table 2. Polysomnographic characteristics of patients with congestive heart failure
(CHF) with CHF etiology due to Chagas’ disease or not.
Chagas’ disease Non-Chagas’ disease
TST (min) 302 ± 83 300 ± 81
Sleep efficiency (%) 73 ± 18 74 ± 17
S1 (%) 12 ± 13 9 ± 8
S2 (%) 62 ± 16 63 ± 10
S3 + 4 (%) 10 ± 8 15 ± 10
REM (%) 13 ± 6 12 ± 7
Arousal I (N/h) 24 ± 14 24 ± 16
AHI (events/h) 20 ± 16 28 ± 23
Mean SaO2 (%) 93 ± 2 93 ± 3
Lowest SaO2 (%) 80 ± 10 82 ± 6
ESS 9 ± 6 11 ± 6
Data are reported as mean ± SD. TST = total sleep time; S1 = sleep stage 1; S2 =
sleep stage 2; S3 + 4 = sleep stage 3 plus sleep stage 4; REM = rapid eye
movement sleep; arousal I = arousal index per hour; AHI = apnea-hypopnea index;
SaO2 = arterial oxygen saturation; ESS = Epworth Sleepiness Scale. There were
no significant differences between groups (Student unpaired t-test).
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Table 3. Demographic, clinical and laboratory findings of pa-
tients with congestive heart failure according to gender.
Male Female
N = 60 (67%) N = 29 (33%)
Age (years) 57 ± 12 59 ± 12
BMI (kg/m2) 26 ± 4 26 ± 6
SBP (mmHg) 123 ± 21 118 ± 34
DBP (mmHg) 79 ± 12 77 ± 15
LVEF (%) 34 ± 6 37 ± 6
NYHA functional class
II 56% 66%
III 32% 24%
IV 12% 10%
Awake arterial blood gases  
Arterial pH 7.36 ± 0.45 7.42 ± 0.03
PaCO2 (mmHg) 37 ± 5 36 ± 5
PaO2 (mmHg) 79 ± 8.5 82 ± 10
Data are reported as mean ± SD or percent. BMI = body mass
index; SBP = systolic blood pressure; DBP = diastolic blood
pressure; LVEF = left ventricular ejection fraction; NYHA = New
York Heart Association; PaCO2 = arterial carbon dioxide tension;
PaO2 = arterial oxygen tension. There were no significant differ-
ences between groups (Student unpaired t-test and Z test).
observed in 33 patients (44%), of whom 26 (79%), 2 (6%),
and 5 (15%) had CSR, OSA and no SDB, respectively,
during PSG recording. Among the 42 (56%) patients with-
out CSR while awake, 10 (23%), 4 (9%), and 28 (66%)
presented CSR, OSA and no SDB, respectively. Eighty-
one (91%) of all patients were followed up for 25 ± 10
months, 8 patients were lost to follow-up either because
their telephone number had changed or because they did
not answer the call. During that period (September 2000 to
March 2004), 22 patients (27%) died. Eighteen patients
(82%) died due to cardiac causes and 4 (18%) due to non-
cardiac causes (1 died during gastric surgery, 1 due to
pneumonia, and 2 of causes associated with renal failure).
Demographic, clinical, and laboratory findings and PSG
data of survivors and non-survivors are shown in Tables 5
and 6, respectively. The proportion of absence of SDB,
CSR and OSA in survivors versus non-survivors was simi-
lar (45, 49 and 6% versus 50, 40, and 10%, respectively).
Non-survivors had lower LVEF and worse NYHA func-
tional classification, less rapid eye movement (REM) sleep,
and a higher proportion of CSR while awake than survi-
vors. The log-rank test showed no differences in mortality
between CHF subgroups: idiopathic (P = 0.57), ischemic
(P = 0.58), and Chagas’ disease (P = 0.73). Mortality was
similar for males (29%) and females (31%; P = 0.41), age
(P = 0.2), and body mass index (P = 0.8). The presence of
SDB (P = 0.9), the AHI (P = 0.41), and the percentage of
REM sleep (P = 0.09) were not associated with mortality. In
contrast, NYHA functional classification (P < 0.001) as well
as the presence of CSR while awake were associated with
higher mortality (P = 0.01; Figure 1). According to the Cox
proportional model, NYHA class IV was significantly asso-
ciated with mortality (relative risk, RR = 3.95, 95%CI =
1.37–11.38, P = 0.011). The presence of CSR while awake
was the only other significant variable, but was of marginal
statistical significance in this model (RR = 2.96, 95%CI =
0.94–9.33, P = 0.064).
Discussion
The results of the present prospective study agree with
previous reports, showing a strikingly high prevalence of
SDB in consecutive CHF patients. Our study extends
current knowledge by showing that: 1) CHF patients with
Chagas’ disease, a common condition in the South Ameri-
can population, had a frequency of SDB similar to that
observed in other etiologies of CHF; 2) men presented
more frequent and more severe SDB than women. These
differences were associated with poor sleep architecture
in men despite similar cardiac function; 3) we did not
demonstrate a significant impact of SDB on mortality. In
Table 4. Polysomnographic characteristics of congestive heart
failure patients according to gender.
Males Females
N = 60 (67%) N = 29 (33%)
TST (min) 288 ± 86 327 ± 63*
Sleep onset (min) 17 ± 23 15 ± 19
Sleep efficiency (%) 71 ± 18 79 ± 14*
S1 (%) 12 ± 11 7 ± 6*
S2 (%) 65 ± 11 58 ± 14*
S3 + 4 (%) 11 ± 9 19 ± 8*
REM (%) 12 ± 7 14 ± 5
Arousal I (N/h) 27 ± 15 20 ± 15
AHI (events/h) 29 ± 23 19 ± 16*
SaO2 mean (%) 93 ± 3 94 ± 2
SaO2 lowest (%) 82 ± 7 82 ± 8
SDB (%) 62% 45%*
CSR (%) 50% 38%
OSA (%) 12% 7%
CSR awake (%) 57% 24%*
ESS 12 ± 5 9 ± 6*
Data are reported as mean ± SD or percent. TST = total sleep
time; S1 = sleep stage 1; S2 = sleep stage 2; S3 + 4 = sleep
stage 3 plus sleep stage 4; REM = rapid eye movement sleep;
arousal I = arousal index per hour; AHI = apnea-hypopnea index;
SDB = sleep-disordered breathing; CSR = Cheyne-Stokes respi-
ration during sleep; OSA = obstructive sleep apnea; CSR awake
= Cheyne-Stokes respiration while awake; ESS = Epworth
Sleepiness Scale.
*P < 0.05 compared to males (Student unpaired t-test).
219
Braz J Med Biol Res 41(3) 2008
Breathing disorders in patients with heart failure
www.bjournal.com.br
Table 5. Demographic, clinical, and laboratory findings of surviv-
ing and non-surviving patients with congestive heart failure.
Survivors (N = 58) Non-survivors (N = 23)
Age (years) 58 ± 11 56 ± 14
Male/female (N; %) 33/18 (65/35%) 13/7 (65/35%)
BMI (kg/m2) 26 ± 6 26 ± 5
SBP (mmHg) 124 ± 27 113 ± 22
DBP (mmHg) 80 ± 12 77 ± 12
LVEF (%) 36.5 ± 5 31.5 ± 7*
NYHA functional class
II 69% 45%
III 25% 30%
IV 6% 25%*
Awake arterial blood gases
Arterial pH 7.42 ± 0.03 7.44 ± 0.03
PaCO2 (mmHg) 37 ± 4 35 ± 7
PaO2 (mmHg) 79 ± 8 81 ± 13
Data are reported as mean ± SD or percent. BMI = body mass
index; SBP = systolic blood pressure; DBP = diastolic blood
pressure; LVEF = left ventricular ejection fraction; NYHA = New
York Heart Association; PaCO2 = arterial carbon dioxide tension;
PaO2 = arterial oxygen tension.
*P < 0.05 compared to survivors (Student unpaired t-test and Z test).
Table 6. Polysomnographic data of surviving and non-surviving
patients with congestive heart failure.
Survivors (N = 58) Non-survivors (N = 23)
TST (min) 315 ± 77 297 ± 89
Sleep efficiency (%) 70 ± 8 70 ± 20
S1 (%) 8 ± 6 10 ± 10
S2 (%) 62 ± 13 67 ± 10
S3 + 4 (%) 14 ± 10 13 ± 9
REM (%) 14 ± 7 9 ± 6*
Arousal I (N/h) 22 ± 14 26 ± 17
AHI (events/h) 25 ± 22 25 ± 22
CSR awake (%) 32% 53%*
ESS 10 ± 6 11 ± 6
Data are reported as mean ± SD or percent. TST = total sleep
time; S1 = sleep stage 1; S2 = sleep stage 2; S3 + 4 = sleep
stage 3 plus sleep stage 4; REM = rapid eye movement sleep;
arousal I = arousal index per hour; AHI = apnea-hypopnea index;
CSR awake = Cheyne-Stokes respiration while awake; ESS =
Epworth Sleepiness Scale.
*P < 0.05 compared to survivors (Student unpaired t-test).
Figure 1. Kaplan-Meier survival curve for patients with Cheyne-
Stokes respiration while awake (CSR awake (+)) or without (CSR
awake (–)). Note that CSR awake (+) patients had a significantly
higher time-adjusted mortality rate (P = 0.01, log-rank test).
contrast, the presence of CSR while awake was associ-
ated with a poor prognosis in univariate analysis and may
have a prognostic value.
The prevalence of SDB in the general population is
more common in men than women (15 vs 9%, respectively,
defined as an AHI >5 events/h of sleep) (26). In agreement
with previous studies, we found that, in our population of
consecutive CHF patients, 81% had AHI >5 and 56% had
AHI >15. The present study extends these findings by
comparing in a prospective study the characteristics of
sleep in men and women with CHF. Women had a signifi-
cantly lower frequency of SDB as well as a significantly
lower overall AHI when compared to men. In addition,
women had better sleep quality. These differences cannot
be accounted for by demographics or LVEF, which were
similar for men and women. Therefore, as is the case for
the general population, women with CHF are protected
from SDB.
The reasons for gender differences in the expression
of SDB are not completely understood. In the general
population, SDB is mainly represented by OSA, and obe-
sity is the major risk factor. Increased fat around the neck,
related to an android pattern of adiposity, may contribute to
pharyngeal narrowing and collapsibility (27). In addition,
the inherent characteristics of pharyngeal tissue and cen-
tral controller may also differ between genders (28). In
CHF patients, SDB is mainly represented by CSR. CSR is
the consequence of respiratory instability, characterized
by hyperventilation in a crescendo-decrescendo pattern
that is interposed by apneas or hypopneas (11). In contrast
to OSA, which is restricted to sleep, the CSR pattern of
breathing may also be present while awake (12,13) as well
as during exercise (14–16). The mechanisms leading to
CSR are not completely understood, but low arterial car-
bon dioxide tension (PaCO2) is one of the key factors
contributing to respiratory instability (29). Patients with
CSR have a low PaCO2 both when awake and asleep (29)
and inhalation of small quantities of CO2 abolishes CSR
(30). The reasons for hyperventilation and low PaCO2 in
patients with CHF are multiple, and include increased
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peripheral and central chemosensitivity as well as pulmo-
nary congestion (29,31,32). Our study agrees with previ-
ous reports showing that CHF patients with CSR have a
lower awake PaCO2 than patients with similar LVEF but no
CSR. The awake PaCO2 was similar in men and women,
suggesting that this is not a mechanism explaining gender
differences in propensity to SDB. However, differences in
the respiratory controller may be present during sleep (33).
Central events occur most frequently during the lighter
stages of non-REM sleep, particularly after arousals and
sleep stage changes. In the general population, males
tend to have a more fragmented sleep than females (34). In
our CHF population, men had a less stable sleep architec-
ture than women, with a larger number of sleep-wake
transitions and shorter slow-wave sleep. Therefore, sleep
instability may help explain the increased risk for CSR
associated with male gender.
The comparison of sleep patterns in patients with CHF
has been previously reported for a retrospective study by
Sin et al. (8). As in Sin’s study, we found that SDB is more
common in men than in women with CHF. The major
difference between Sin’s study and ours is that we found a
lower prevalence of OSA in our women (14%) compared to
theirs (31%). One possible explanation for this difference
is that there is no clear-cut separation between obstructive
and central apneas, and different criteria may have been
employed in the two studies. In patients with CHF, OSA
and CSR may be difficult to distinguish. Furthermore,
patients with CHF may experience a conversion of pre-
dominantly obstructive to predominantly central respira-
tory events over a single night (35). On the other hand,
differences between studies may be accounted for by
differences in study design. Suspicion of SDB was one
criterion for referral to Sin’s retrospective study (8). Be-
cause OSA is the major cause for sleep laboratory refer-
rals, this may have biased their study sample toward a
higher prevalence of OSA. In contrast, our study recruited
consecutive patients at the heart failure clinic. Supporting
this finding is the fact that the proportion of OSA found in
our study is much closer to Javaheri’s prospective studies
in patients with CHF (19,23).
The results of our study agree with reports (8,32)
demonstrating that patients with CHF have very poor sleep
quality, as shown by low sleep efficiency. The poor sleep
quality cannot be attributed to SDB alone and may be
caused by the underlying disease state. The absence of
difference in daytime sleepiness assessed by the Epworth
Sleepiness Scale in CHF patients with and without SDB
has also been previously reported (36). Therefore, despite
the high prevalence of SDB in patients with CHF, even in
patients with Chagas’ disease, the symptoms of disturbed
sleep overlap with the CHF symptoms, making it difficult to
recognize SDB based on symptoms alone.
To the best of our knowledge, ours is the first study to
investigate sleep in patients with Chagas’ disease, an
important cause of CHF in Latin America that has unique
characteristics (37). For instance, the congestive phenom-
enon of heart failure in Chagas’ disease is usually more
intense in the systemic than in the pulmonary circulation
(10). Because pulmonary congestion may cause hyper-
ventilation and low PaCO2 (a major cause of respiratory
instability, as previously discussed), we initially hypoth-
esized that patients with Chagas’ disease would be pro-
tected against CSR. However, we demonstrated that the
sleep pattern and the prevalence of SDB, including pres-
ence of CSR, was similar across CHF etiology, including
those patients with Chagas’ disease. Our data support the
concept that CHF is the final pathway of several cardiac
etiologies. Once CHF is established, it triggers a large
number of stereotyped responses that, at this point, are
independent of the original etiology.
There is recent evidence that OSA is associated with
increased mortality in patient with CHF (7). In contrast, the
information on the impact of CSR on mortality is contradic-
tory. In our study, CSR during sleep was not related to
overall mortality in CHF, which is in agreement with some
(13,18) but in conflict with other reports (4,5,19). Signifi-
cant variations between studies, including population char-
acteristics, monitoring system, and definitions may ac-
count for these contradictory results (18). In contrast to
sleep, the studies on the significance of CSR at rest while
awake are more consistent, and systematically show a
worse prognosis (13,16). Sharing several similarities with
CSR while awake, some studies have shown a poor prog-
nostic value of exercise-related periodic breathing (14,15).
Exercise-related periodic breathing may correspond to a
mild form of CSR, in which cyclic oscillations in ventilation
occur. Recently, Corrà et al. (16) suggested that CSR
while awake is significantly associated with SDB (AHI
>30), and that their combination represents a crucial prog-
nostic burden in patients with CHF. However, these au-
thors did not monitor sleep but only performed respiratory
screening, and it is not clear if the CSR observed during the
night occurred during sleep or wakefulness. Our study
shares similarities with a report by Andreas et al. (13) who
also showed that CSR while awake, but not during sleep,
predicted mortality. In the present study we found, in
agreement with previous studies (4), that LVEF and NYHA
category were predictors of mortality. The observation that
CSR while awake did not remain statistically significant in
multivariate analysis may be the result of a low statistical
power of the study. Alternatively, CSR may just be a
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marker of low cardiac performance illustrated by a general
measure represented by the cardiac functional class.
Our study has several potential limitations. First, only
19% of the patients studied were on ß-blockers, a relatively
small number when compared with current guidelines (38).
There is some evidence that ß-blockers may be associ-
ated with a decrease in the prevalence and severity of CSR
(39,40). Therefore, the absolute prevalence of CSR must
be interpreted with caution. Second, the number of pa-
tients with OSA (N = 9), women (N = 29) as well as patients
with Chagas’ disease (N = 25) was relatively small and did
not permit a separate mortality analysis in these groups.
However, this is the first prospective study to show signifi-
cant gender differences in sleep in groups with similar
anthropometric and cardiac function. Finally, the marginal
significance of CSR while awake in predicting mortality
does not allow definitive conclusions and may also be the
result of a limited number of patients evaluated during
follow-up.
Our nonselected, consecutive patients with severe CHF
had high prevalence of SDB irrespective of etiology. Men
had a higher prevalence of SDB, more severe SDB and
worse sleep quality than women. Presence of CSR while
awake, but not during sleep, may be a marker of poor
prognosis in patients with CHF.
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